Emerging adult age status predicts poor buprenorphine treatment retention

Journal of Substance Abuse Treatment

Volumn 47, Issue 3, 2014, Pages 202-212

  Schuman Olivier, Zev ^a,b   Weiss, Roger D ^a   Hoeppner, Bettina B ^a   Borodovsky, Jacob ^a   Albanese, Mark J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DARTMOUTH PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Buprenorphine; Development; Emerging adult; Opioid dependence; Outcome; Retention; Toxicology; Treatment; Young adult

Indexed keywords

BUPRENORPHINE; ILLICIT DRUG; NALOXONE; OPIATE; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; COMPARATIVE STUDY; DRUG RETENTION; ELECTRONIC MEDICAL RECORD; FAMILY MEDICINE; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSOCIAL REHABILITATION; RELAPSE; RETROSPECTIVE STUDY; SUBSTANCE ABUSE; SUBSTANCE USE DISORDER; URINE TOXICOLOGY; ADOLESCENT; AGING; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; PATIENT DROPOUT; PSYCHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGING; BUPRENORPHINE; FEMALE; HUMANS; MALE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; PATIENT DROPOUTS; RECURRENCE; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904676347     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2014.04.006     Document Type: Article

References (73)

1. Alford D.P., LaBelle C.T., Kretsch N., Bergeron A., Winter M., Botticelli M., et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience. Archives of Internal Medicine 2011, 171(5):425-431.
2. Arnett J.J. Emerging adulthood. A theory of development from the late teens through the twenties. American Psychologist 2000, 55(5):469-480.
3. Arnett J.J. The developmental context of substance use in emerging adulthood. Journal of Drug Issues 2005, 35(2):235-254.
4. Arnett J.J. Emerging adulthood(s): The cultural psychology of a new life stage. Bridging Cultural and Developmental Approaches to Psychology 2011, 255-275. Oxford University Press. L.A. Jensen (Ed.).
5. Casey B.J., Jones R.M. Neurobiology of the adolescent brain and behavior: Implications for substance use disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2010, 49(12):1189-1201.
6. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Statistics in Medicine 2000, 19(22):3127-3131.
7. Cicero T.J., Ellis M.S., Surratt H.L. Effect of abuse-deterrent formulation of OxyContin. New England Journal of Medicine 2012, 367(2):187-189.
8. Clausen T., Anchersen K., Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study. Drug and Alcohol Dependence 2008, 94(1-3):151-157.
9. Darke S., Ross J., Teesson M., Ali R., Cooke R., Ritter A., et al. Factors associated with 12months continuous heroin abstinence: Findings from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment 2005, 28(3):255-263.
10. Dreifuss J.A., Griffin M.L., Frost K., Fitzmaurice G.M., Potter J.S., Fiellin D.A., et al. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug and Alcohol Dependence 2013, 131(1-2):112-118.
11. Fareed A., Vayalapalli S., Casarella J., Drexler K. Effect of buprenorphine dose on treatment outcome. Journal of Addictive Diseases 2012, 31(1):8-18.
12. Fiellin D.A., Moore B.A., Sullivan L.E., Becker W.C., Pantalon M.V., Chawarski M.C., et al. Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5years. American Journal on Addictions 2008, 17(2):116-120.
13. Finney J.W., Moos R.H. Entering treatment for alcohol abuse: A stress and coping model. Addiction 1995, 90(9):1223-1240.
14. Fox S. Mobile Health 2012. Pew Internet & American Life Project 2012, (from http://pewinternet.org/~/media//Files/Reports/2012/PIP_MobileHealth2012_FINAL.pdf).
15. Fudala P.J., Bridge T.P., Herbert S., Williford W.O., Chiang C.N., Jones K., et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine 2003, 349(10):949-958.
16. Giedd J.N., Blumenthal J., Jeffries N.O., Castellanos F.X., Liu H., Zijdenbos A., et al. Brain development during childhood and adolescence: A longitudinal MRI study. Nature Neuroscience 1999, 2(10):861-863.
17. Gogtay N., Giedd J.N., Lusk L., Hayashi K.M., Greenstein D., Vaituzis A.C., et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(21):8174-8179.
18. Grella C.E., Hser Y.I., Joshi V., Anglin M.D. Patient histories, retention, and outcome models for younger and older adults in DATOS. Drug and Alcohol Dependence 1999, 57(2):151-166.
19. Gunderson E.W., Fiellin D.A. Office-based maintenance treatment of opioid dependence: How does it compare with traditional approaches?. CNS Drugs 2008, 22(2):99-111.
20. Hanson K.L., Medina K.L., Padula C.B., Tapert S.F., Brown S.A. Impact of adolescent alcohol and drug use on neuropsychological functioning in young adulthood: 10-Year outcomes. Journal of Child & Adolescent Substance Abuse 2011, 20(2):135-154.
21. Hartzler B., Rabun C. Community opioid treatment perspectives on contingency management: Perceived feasibility, effectiveness, and transportability of social and financial incentives. Journal of Substance Abuse Treatment 2013, 45(2):242-248.
22. Heflinger C.A., Hoffman C. Transition age youth in publicly funded systems: Identifying high-risk youth for policy planning and improved service delivery. Journal of Behavioral Health Services and Research 2008, 35(4):390-401.
23. Jacobus J., McQueeny T., Bava S., Schweinsburg B.C., Frank L.R., Yang T.T., et al. White matter integrity in adolescents with histories of marijuana use and binge drinking. Neurotoxicology and Teratology 2009, 31(6):349-355.
24. Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992, 267(20):2750-2755.
25. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the future national survey results on drug use, 1975-2012: Volume I, secondary school students 2013, Institute for Social Research, The University of Michigan, Ann Arbor.
26. Jones C.M. Frequency of prescription pain reliever nonmedical use: 2002-2003 and 2009-2010. Archives of Internal Medicine 2012, 172(16):1265-1267.
27. Kellam H. The neuro-developmental pathway origins of addiction. Early Brain Development and Addiction for Undergraduate Medical Education 2013, ([podcast] Retrieved on 8/31/2013 from http://chec-cesc.afmc.ca/resource/the-neuro-developmental-pathway-origins-of-addiction-an-ebbda-introductory-podcast).
28. Kelly J.F., Brown S.A., Abrantes A., Kahler C.W., Myers M. Social recovery model: An 8-year investigation of adolescent 12-step group involvement following inpatient treatment. Alcoholism, Clinical and Experimental Research 2008, 32(8):1468-1478.
29. Kelly J.F., Urbanoski K.A., Hoeppner B.B., Slaymaker V. "Ready, willing, and (not) able" to change: Young adults' response to residential treatment. Drug and Alcohol Dependence 2012, 121(3):224-230.
30. Klostermann K., O'Farrell T.J. Treating substance abuse: Partner and family approaches. Social Work in Public Health 2013, 28(3-4):234-247.
31. Lebel C., Beaulieu C. Longitudinal development of human brain wiring continues from childhood into adulthood. Journal of Neuroscience 2011, 31(30):10937-10947.
32. Malone D.T., Hill M.N., Rubino T. Adolescent cannabis use and psychosis: Epidemiology and neurodevelopmental models. British Journal of Pharmacology 2010, 160(3):511-522.
33. Marsch L.A., Stephens M.A., Mudric T., Strain E.C., Bigelow G.E., Johnson R.E. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Experimental and Clinical Psychopharmacology 2005, 13(4):293-302.
34. Marsh R., Gerber A.J., Peterson B.S. Neuroimaging studies of normal brain development and their relevance for understanding childhood neuropsychiatric disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2008, 47(11):1233-1251.
35. McHugh R.K., Murray H.W., Hearon B.A., Pratt E.M., Pollack M.H., Safren S.A., et al. Predictors of dropout from psychosocial treatment in opioid-dependent outpatients. American Journal on Addictions 2013, 22(1):18-22.
36. McKellar J., Kelly J., Harris A., Moos R. Pretreatment and during treatment risk factors for dropout among patients with substance use disorders. Addictive Behaviors 2006, 31(3):450-460.
37. McTavish F.M., Chih M.Y., Shah D., Gustafson D.H. How patients recovering from alcoholism use a smartphone intervention. Journal of Dual Diagnosis 2012, 8(4):294-304.
38. Medina K.L., Schweinsburg A.D., Cohen-Zion M., Nagel B.J., Tapert S.F. Effects of alcohol and combined marijuana and alcohol use during adolescence on hippocampal volume and asymmetry. Neurotoxicology and Teratology 2007, 29(1):141-152.
39. Mueser K.T., Bond G.R., Drake R.E., Resnick S.G. Models of community care for severe mental illness: A review of research on case management. Schizophrenia Bulletin 1998, 24(1):37-74.
40. Ohlin L., Hesse M., Fridell M., Tatting P. Poly-substance use and antisocial personality traits at admission predict cumulative retention in a buprenorphine programme with mandatory work and high compliance profile. BMC Psychiatry 2011, 11:81.
41. Okie S. A flood of opioids, a rising tide of deaths. New England Journal of Medicine 2010, 363(21):1981-1985.
42. Pani P.P., Maremmani I., Pirastu R., Tagliamonte A., Gessa G.L. Buprenorphine: A controlled clinical trial in the treatment of opioid dependence. Drug and Alcohol Dependence 2000, 60(1):39-50.
43. Petry N.M., Carroll K.M. Contingency management is efficacious in opioid-dependent outpatients not maintained on agonist pharmacotherapy. Psychology of Addictive Behaviors 2013, 27(4):1036-1043.
44. Pew Cell phone and smartphone ownership over time. Pew Internet & American Life Project 2013, (from http://www.pewinternet.org/Trend-Data-%28Adults%29/Device-Ownership.aspx).
45. Rosenstock I.M. Why people use health services. The Milbank Memorial Fund Quarterly 1966, 44(3 Suppl.):94-127.
46. Saitz R., Larson M.J., Labelle C., Richardson J., Samet J.H. The case for chronic disease management for addiction. Journal of Addiction Medicine 2008, 2(2):55-65.
47. SAMHSA The TEDS Report: Characteristics of substance abuse treatment admissions reporting primary abuse of prescription pain relievers: 1998 and 2008 2010, Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Rockville, MD.
48. SAMHSA Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings NSDUH Series H-44, HHS Publication No. (SMA) 12-4713 2012, Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Rockville, MD.
49. SAMHSA Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings 2013, (Rockville, MD).
50. SAMHSA Buprenorphine physician and program treatment locator Retrieved 5/19/2013, from. http://buprenorphine.samhsa.gov/bwns_locator/dr_search.htm.
51. Schuman-Olivier Z., Albanese M., Nelson S.E., Roland L., Puopolo F., Klinker L., et al. Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers. Journal of Substance Abuse Treatment 2010, 39(1):41-50.
52. Schuman-Olivier Z., Hoeppner B.B., Weiss R.D., Borodovsky J., Shaffer H.J., Albanese M.J. Benzodiazepine use during buprenorphine treatment for opioid dependence: Clinical and safety outcomes. Drug and Alcohol Dependence 2013, 132(3):580-586.
53. Sheidow A.J., McCart M., Zajac K., Davis M. Prevalence and impact of substance use among emerging adults with serious mental health conditions. Psychiatric Rehabilitation Journal 2012, 35(3):235-243.
54. Shin S.H., Lundgren L., Chassler D. Examining drug treatment entry patterns among young injection drug users. American Journal of Drug and Alcohol Abuse 2007, 33(2):217-225.
55. Simpson D.D., Joe G.W., Rowan-Szal G.A. Drug abuse treatment retention and process effects on follow-up outcomes. Drug and Alcohol Dependence 1997, 47(3):227-235.
56. Smith A. Mobile Access 2010. Pew Internet & American Life Project 2010, (from http://pewinternet.org/~/media//Files/Reports/2010/PIP_Mobile_Access_2010.pdf).
57. Smith A. Smartphone ownership-2013 update. Pew Internet & American Life Project 2013, (from http://pewinternet.org/~/media//Files/Reports/2013/PIP_Smartphone_adoption_2013.pdf).
58. Smith D.C., Cleeland L., Dennis M.L. Reasons for quitting among emerging adults and adolescents in substance-use-disorder treatment. Journal of Studies on Alcohol and Drugs 2010, 71(3):400-409.
59. Smith D.C., Cleeland L., Middleton A., Godley M.D. Willingness and appropriateness of peers participating in emerging adults' substance misuse treatment. Journal of Substance Abuse Treatment 2013, 45(1):148-154.
60. Smith D.C., Godley S.H., Godley M.D., Dennis M.L. Adolescent Community Reinforcement Approach outcomes differ among emerging adults and adolescents. Journal of Substance Abuse Treatment 2011, 41(4):422-430.
61. Soeffing J.M., Martin L.D., Fingerhood M.I., Jasinski D.R., Rastegar D.A. Buprenorphine maintenance treatment in a primary care setting: Outcomes at 1year. Journal of Substance Abuse Treatment 2009, 37(4):426-430.
62. Soyka M., Zingg C., Koller G., Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study. International Journal of Neuropsychopharmacology 2008, 11(5):641-653.
63. Stone A.L., Becker L.G., Huber A.M., Catalano R.F. Review of risk and protective factors of substance use and problem use in emerging adulthood. Addictive Behaviors 2012, 37(7):747-775.
64. Subramaniam G.A., Ives M.L., Stitzer M.L., Dennis M.L. The added risk of opioid problem use among treatment-seeking youth with marijuana and/or alcohol problem use. Addiction 2010, 105(4):686-698.
65. Subramaniam G.A., Warden D., Minhajuddin A., Fishman M.J., Stitzer M.L., Adinoff B., et al. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. Journal of the American Academy of Child and Adolescent Psychiatry 2011, 50(11):1120-1128.
66. Sullivan L.E., Moore B.A., O'Connor P.G., Barry D.T., Chawarski M.C., Schottenfeld R.S., et al. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. American Journal on Addictions 2010, 19(1):53-58.
67. Uosukainen H., Pentikainen H., Tacke U. The effect of an electronic medicine dispenser on diversion of buprenorphine-naloxone-experience from a medium-sized Finnish city. Journal of Substance Abuse Treatment 2013, 45(1):143-147.
68. Warden D., Subramaniam G.A., Carmody T., Woody G.E., Minhajuddin A., Poole S.A., et al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addictive Behaviors 2012, 37(9):1046-1053.
69. Warner M., Chen L.H., Makuc D.M., Anderson R.N., Minino A.M. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief 2011, (81):1-8.
70. Weiss R.D., Potter J.S., Fiellin D.A., Byrne M., Connery H.S., Dickinson W., et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Archives of General Psychiatry 2011, 68(12):1238-1246.
71. Woody G.E., Poole S.A., Subramaniam G., Dugosh K., Bogenschutz M., Abbott P., et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. JAMA 2008, 300(17):2003-2011.
72. Wright T.M., Myrick H., Malcolm R., Randall P., Boyle E., Henderson S., et al. Impact of lifetime alcohol quit attempts and medicated detoxifications on time to relapse during an index alcohol detoxification. Journal of Addiction Medicine 2007, 1(1):15-20.
73. Zhang Z., Friedmann P.D., Gerstein D.R. Does retention matter? Treatment duration and improvement in drug use. Addiction 2003, 98(5):673-684.